Latest Safety News

Page 13 of 252
Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
Ada Torres
Ada Torres
8 Oct 2026
An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.
Ada Torres
Ada Torres
7 Oct 2026
Arovella Therapeutics has released a second clinical batch of its off-the-shelf CAR-iNKT therapy ALA-101, with material expected to support dose escalation and the start of dose expansion in blood cancers. The company is also adding hospital sites ahead of anticipated first-patient dosing in late October.
Ada Torres
Ada Torres
7 Oct 2026
The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.
Ada Torres
Ada Torres
6 Oct 2026
Aquirian has completed its Wubin Energetics Hub upgrade within budget and is preparing Drillforce to begin work at Brightstar Resources’ Lord Byron project under a contract valued at approximately $48 million over three years. The company also says Collar Keeper sales remain strong, while a biodegradable version moves towards commercialisation.
Victor Sage
Victor Sage
6 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026
CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.
Victor Sage
Victor Sage
5 Oct 2026
Alkane Resources has reported a transformational FY2026, with the Mandalay merger helping lift revenue to A$935.8 million and profit after tax to A$228.7 million. The enlarged gold and antimony producer has also declared its first dividend and approved a buy-back, while setting broadly stable production guidance for FY2027.
Maxwell Dee
Maxwell Dee
2 Oct 2026
Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.
Victor Sage
Victor Sage
2 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
BSA is proposing to acquire aerial infrastructure technology business Eonetics in a largely scrip-based transaction that would leave the sellers with about 39.9% of BSA. The deal remains non-binding, with one seller yet to sign and multiple approvals still required.
Victor Sage
Victor Sage
1 Oct 2026
Acusensus has exercised a second six-month extension to its NSW mobile speed camera agreement, adding an estimated $16 million in contracted value through June 2027. The more consequential question remains unresolved: whether the company can convert the ongoing tender into a longer-term deal.
Sophie Babbage
Sophie Babbage
1 Oct 2026

Browse the archive

Full archive